Genedrive reveals bid to raise more than £10m to fund future growth

A Manchester-based molecular diagnostics company has revealed plans to raise more than £10m.

Genedrive, which is listed on AIM, has announced a proposed fundraising by the placing of new shares to raise up to £6m.

The company is also to make an open offer to qualifying shareholders to raise up to £4.5m.

READ MORE: Premiership rugby club Sale Sharks eye joint bid with Class of 92-owned Salford City to buy AJ Bell Stadium

In a statement, the business said the net proceeds of the fundraising and its existing cash resources will be directed towards “two near-term revenue opportunities” – the final development of the Genedrive COV19 ID Kit and supporting the commercial roll out of the company’s Antibiotic Induced Hearing Loss test, Genedrive MT-RNR1 ID Kit.

The money will also provide additional funding to cover the group’s other product development, commercialisation and general corporate costs until the AIHL test and GDR COV POC are expected to be able to support its overheads.

The placing is expected to take place on or around September 14.

Sign up for your free North West newsletter – and follow us on LinkedIn!

Email newsletters

BusinessLive is your home for business news from around the North West- and you can stay in touch with all the latest news from Greater Manchester, Liverpool City Region, Cheshire, Lancashire and Cumbria through our email alerts.

You can sign up to receive daily morning news bulletins from every region we cover and to weekly email bulletins covering key economic sectors from manufacturing to technology and enterprise. And we’ll send out breaking news alerts for any stories we think you can’t miss.

Visit our email preference centre to sign up to all the latest news from BusinessLive.

LinkedIn

For all the latest stories, views, polls and more, follow our BusinessLive North West LinkedIn page here.

Peel Hunt and finnCap are acting as joint bookrunners.

Peel Hunt is acting as nominated adviser, in connection with the placing.

The company’s unaudited revenues to June 30 2021 are £700,000, split roughly equally between the DoD and the Genedrive 96-SARS-CoV-2 test.

The estimated loss for the year is £800,000 after a tax credit of £1.2m and finance income of £3.5m as a result of a gain on the conversion of loan notes.

Business Live – North West